James M. Pauff, MD, PhD
Clinical Investigator, Sarah Cannon Research Institute
James Pauff, MD, PhD, is an associate at Tennessee Oncology and Clinical Investigator with Sarah Cannon Research Institute. He is helping to lead and grow the Sarah Cannon Research Institute at Tennessee Oncology Franklin Drug Development Unit by working to advance novel therapies for patients facing cancer throughout Middle Tennessee.
Prior to joining Sarah Cannon, Pauff served as an associate medical director of clinical development, oncology, and was previously an associate medical director in the physician development program at AbbVie in Chicago. While at AbbVie, he served as study team lead for venetoclax in multiple myeloma and as clinical strategy lead for venetoclax in breast cancer, he also received a 2019 R&D President’s Award for his work on the CLL Collaborative Study of Real World Evidence (CORE). In addition, he served as a physician of medical oncology at Froedtert South Medical Group in Kenosha, Wis., where he handled inpatient consultation services at Kenosha and St. Catherine’s Medical Center campuses with outpatient clinical care at St. Catherine’s Medical Center campus. He also served as attending physician of medical oncology and of hospital medicine with Mercyhealth, Mercy Hospital & Trauma Center in Janesville, Wis.
Pauff completed his Clinical Fellowship in Hematology & Oncology at Vanderbilt University Medical Center. He also completed his internship and residency at Vanderbilt University Medical Center, and earned both his Doctor of Medicine and PhD from the Ohio State University.